Issue 2/2022
Content (14 Articles)
Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan
Imad Treish, Abeer Al Rabayah, Saad Jaddoua, Haitham Tuffaha
Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review
Ana-Catarina Pinho-Gomes, John Cairns
Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis
Amir Ansaripour, Kari Roehrich, Atefeh Mashayekhi, Mwanamisi Wanjala, Shani Noel, Mohsen Rezaei Hemami, Angela Murray, Mehdi Javanbakht
Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial
Bettina Wulff Risør, Ditte Hoffmann Frydendal, Marie Konge Villemoes, Camilla Palmhøj Nielsen, Charlotte Ulrikka Rask, Lisbeth Frostholm
Examining Ways to Improve Weight Control Programs’ Population Reach and Representativeness: A Discrete Choice Experiment of Financial Incentives
Wen You, Yuan Yuan, Kevin J. Boyle, Tzeyu L. Michaud, Chris Parmeter, Richard W. Seidel, Paul A. Estabrooks
Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study
Pedro Labisa, Valeska Andreozzi, Melina Mota, Susana Monteiro, Rita Alves, João Almeida, Björn Vandewalle, Jorge Felix, Katharina Buesch, Hugo Canhão, Igor Beitia Ortiz de Zarate
Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018
Rose J. Geurten, Jeroen N. Struijs, Arianne M. J. Elissen, Henk J. G. Bilo, Chantal van Tilburg, Dirk Ruwaard
Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States
Siu Hing Lo, Andrew Lloyd, Shuayb Elkhalifa, Zlatko Sisic, Floortje E. van Nooten
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
Will Dunlop, Marjolijn van Keep, Peter Elroy, Ignacio Diaz Perez, Mario J. N. M. Ouwens, Tina Sarbajna, Yiduo Zhang, Alastair Greystoke
Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada
Patrick Berrigan, Geoffrey G. Hicks, Wendy J. Ungar, Jennifer D. Zwicker
The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation
Ahmed H. Seddik, Nima Melzer, Foteini Tsotra, Dennis A. Ostwald
Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
Ahmed Alghamdi, Bander Balkhi, Abdulaziz Altowaijri, Nasser Al-shehri, Lewis Ralph, Emily-Ruth Marriott, Michael Urbich, Fawaz Aljanad, Rima Aziziyeh
Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium
B. Gillain, G. Degraeve, T. Dreesen, G. De Bruecker, E. Buntinx, D. Beke, C. Kestens, E. Valassopoulou, F. Verhelst, E. Peeters, S. Pype, C. De Vos, D. Strens, I. Vandersmissen
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Dikshyanta Rana, Claudia Geue, Kelly Baillie, Jiafeng Pan, Tanja Mueller, Jennifer Laskey, Marion Bennie, Julie Clarke, Robert J. Jones, Ailsa Brown, Olivia Wu